Pds Biotechnology Corp Stock Analysis
| PDSB Stock | USD 1.26 0.01 0.79% |
PDS Biotechnology Corp is overvalued with Real Value of 1.21 and Target Price of 11.5. The main objective of PDS Biotechnology stock analysis is to determine its intrinsic value, which is an estimate of what PDS Biotechnology Corp is worth, separate from its market price. There are two main types of PDS Biotechnology's stock analysis: fundamental analysis and technical analysis.
The PDS Biotechnology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and PDS Biotechnology's ongoing operational relationships across important fundamental and technical indicators.
PDS |
PDS Stock Analysis Notes
The book value of the company was at this time reported as 0.6. The company recorded a loss per share of 1.17. PDS Biotechnology Corp last dividend was issued on the 18th of March 2019. The entity had 1:20 split on the 18th of March 2019. PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey. Pds Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. To find out more about PDS Biotechnology Corp contact Frank BeduAddo at 800 208 3343 or learn more at https://www.pdsbiotech.com.PDS Biotechnology Corp Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. PDS Biotechnology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding PDS Biotechnology Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| PDS Biotechnology generated a negative expected return over the last 90 days | |
| PDS Biotechnology has high historical volatility and very poor performance | |
| PDS Biotechnology may become a speculative penny stock | |
| PDS Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PDS Biotechnology Corp currently holds about 52.98 M in cash with (33.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from businesswire.com: Calque Partners with EDGE Home Finance to Provide Buy-Before-You-Sell Programs That Convert Equity to Cash |
PDS Biotechnology Corp Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to PDS Biotechnology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
PDS Largest EPS Surprises
Earnings surprises can significantly impact PDS Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-10 | 2021-09-30 | -0.2 | -0.24 | -0.04 | 20 | ||
2020-08-13 | 2020-06-30 | -0.23 | -0.19 | 0.04 | 17 | ||
2021-05-13 | 2021-03-31 | -0.19 | -0.14 | 0.05 | 26 |
PDS Stock Institutional Investors
| Shares | Integrys Wealth Advisors Llc | 2024-12-31 | 73.5 K | Two Sigma Investments Llc | 2024-12-31 | 65.7 K | Virtu Financial Llc | 2024-12-31 | 54.7 K | Ubs Group Ag | 2024-12-31 | 50.1 K | Vontobel Holding Ltd. | 2024-12-31 | 40 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 39 K | Jane Street Group Llc | 2024-12-31 | 35.6 K | Bank Of New York Mellon Corp | 2024-12-31 | 29.3 K | Bank Of America Corp | 2024-12-31 | 26.9 K | Vanguard Group Inc | 2024-12-31 | 1.5 M | Blackrock Inc | 2024-12-31 | 523.1 K |
PDS Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 47.14 M.PDS Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (1.08) | (1.14) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (1.89) | (1.80) |
Management Efficiency
PDS Biotechnology Corp has return on total asset (ROA) of (0.4488) % which means that it has lost $0.4488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7449) %, meaning that it created substantial loss on money invested by shareholders. PDS Biotechnology's management efficiency ratios could be used to measure how well PDS Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to -0.68. In addition to that, Return On Capital Employed is expected to decline to -1.14. The current year's Net Tangible Assets is expected to grow to about 53.1 M, whereas Total Assets are forecasted to decline to about 64.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.97 | 0.92 | |
| Tangible Book Value Per Share | 0.97 | 0.92 | |
| Enterprise Value Over EBITDA | (2.72) | (2.86) | |
| Price Book Value Ratio | 5.30 | 5.56 | |
| Enterprise Value Multiple | (2.72) | (2.86) | |
| Price Fair Value | 5.30 | 5.56 | |
| Enterprise Value | 294.4 M | 309.2 M |
Leadership at PDS Biotechnology emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 26th of February, PDS Biotechnology holds the Market Risk Adjusted Performance of (0.30), risk adjusted performance of (0.07), and Coefficient Of Variation of (978.60). Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of PDS Biotechnology, as well as the relationship between them.PDS Biotechnology Corp Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. PDS Biotechnology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for PDS Biotechnology Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
PDS Biotechnology Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PDS Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on PDS Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PDS Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PDS Biotechnology Outstanding Bonds
PDS Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PDS Biotechnology Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PDS bonds can be classified according to their maturity, which is the date when PDS Biotechnology Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US70462GAC24 Corp BondUS70462GAC24 | View | |
| US70462GAB41 Corp BondUS70462GAB41 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
PDS Biotechnology Predictive Daily Indicators
PDS Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PDS Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
PDS Biotechnology Forecast Models
PDS Biotechnology's time-series forecasting models are one of many PDS Biotechnology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PDS Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About PDS Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how PDS Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PDS shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as PDS Biotechnology. By using and applying PDS Stock analysis, traders can create a robust methodology for identifying PDS entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current PDS Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. PDS analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. PDS analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 11.5 | Strong Buy | 5 | Odds |
Most PDS analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand PDS stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of PDS Biotechnology Corp, talking to its executives and customers, or listening to PDS conference calls.
PDS Stock Analysis Indicators
PDS Biotechnology Corp stock analysis indicators help investors evaluate how PDS Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading PDS Biotechnology shares will generate the highest return on investment. By understating and applying PDS Biotechnology stock analysis, traders can identify PDS Biotechnology position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 73.8 M | |
| Long Term Debt | 19.5 M | |
| Common Stock Shares Outstanding | 31 M | |
| Total Stockholder Equity | 26.1 M | |
| Tax Provision | -1.4 M | |
| Property Plant And Equipment Net | 335 K | |
| Cash And Short Term Investments | 56.6 M | |
| Cash | 56.6 M | |
| Accounts Payable | 7 M | |
| Net Debt | -32.7 M | |
| 50 Day M A | 1.6022 | |
| Total Current Liabilities | 13.6 M | |
| Other Operating Expenses | 43 M | |
| Non Current Assets Total | 335 K | |
| Non Currrent Assets Other | -1.00 | |
| Stock Based Compensation | 7.6 M |
Complementary Tools for PDS Stock analysis
When running PDS Biotechnology's price analysis, check to measure PDS Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PDS Biotechnology is operating at the current time. Most of PDS Biotechnology's value examination focuses on studying past and present price action to predict the probability of PDS Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PDS Biotechnology's price. Additionally, you may evaluate how the addition of PDS Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |